Zosano Pharma Stock Forecast, Price & News

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZSAN shares have increased by 186.1% and is now trading at $1.62.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zosano Pharma.

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Zosano Pharma.

Zosano Pharma Corp (NASDAQ:ZSAN) posted its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14).
View Zosano Pharma's earnings history.

Zosano Pharma shares reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

4 brokerages have issued 1-year price objectives for Zosano Pharma's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Zosano Pharma's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 193.2% from the stock's current price.
View analysts' price targets for Zosano Pharma.

Zosano Pharma saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,820,000 shares, an increase of 26.5% from the August 31st total of 5,390,000 shares. Based on an average trading volume of 5,000,000 shares, the short-interest ratio is currently 1.4 days.
View Zosano Pharma's Short Interest.

Some companies that are related to Zosano Pharma include Cue Biopharma (CUE), G1 Therapeutics (GTHX), Altimmune (ALT), resTORbio (TORC), 89bio (ETNB), Odonate Therapeutics (ODT), Avid Bioservices (CDMO), MannKind (MNKD), TherapeuticsMD (TXMD), Amryt Pharma (AMYT), Viking Therapeutics (VKTX), Kala Pharmaceuticals (KALA), Rigel Pharmaceuticals (RIGL), Organogenesis (ORGO) and Syros Pharmaceuticals (SYRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include AEterna Zentaris (AEZS), Pennsylvania R.E.I.T. (PEI), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Hallador Energy (HNRG) and EnLink Midstream (ENLC).

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $1.62.

Zosano Pharma has a market capitalization of $111.10 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.

The official website for Zosano Pharma is www.zosanopharma.com.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]